Brief: Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D
06/02/2020 12:49
Feb 6 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX ANNOUNCES THREE ORAL PRESENTATIONS HIGHLIGHTING
SEMAPHORIN 4D (SEMA4D) AT THE ASCO-SITC CLINICAL IMMUNO-ONCOLOGY
SYMPOSIUM
Source text for Eikon: ID:nGNX5Rzp6F
Further company coverage: VCNX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease